Abstract
In this study, we aimed to elucidate the role of PBMC gene expression in ICI treatment response and prognosis. According to Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST version 1.1), patients with no disease progression (PD) or tumor-induced deaths within 6 months of anti-PD-1/PD-L1 treatment, including those with complete response (CR), partial response (PR), or stable disease (SD), were grouped as ICI responders. Currently, the cause-and-effect relationship is not fully understood; however, our study proposes that the loss of chromosome Y (LOY) or extreme downregulation of chromosome Y (EDY) in immune cells may lead to a decrease in the proportion of lymphocytes, thereby resulting in primary resistance to PD-1/PD-L1 blockade immunotherapy. [...]DDX3Y and USP9Y emerge as useful biomarkers for predicting PD-1/PD-L1 blockade response.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China; Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
2 Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
3 Department of Thoracic Cancer, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
4 Department of Laboratory Medicine, The First Affiliated Hospital of Hainan Medical College, Haikou, Hainan 570102, China